Saturday, December 06, 2014 1:04:49 PM
Increasing institutional holders? Last I saw this was almost entirely retail. Is there information I'm missing? I could be wrong but I have seen very little interest in this stock from institutions.
Overall I've been following this stock for about a year and I've been invested for much of that time. I spend a lot of my free time researching the company and the technology. And unfortunately I think it's time to sell. I wish it wasn't so but I don't use hope as an investment strategy.
I want to own the stock more than anything. I want to believe in the story. Unfortunately reality might be different. This company has not demonstrated any potential for significant returns until far in the future. As far as I can tell the only hope for significant returns is when they can create organs and this won't happen for many years.
When the company demonstrates that it is more than just a research organization I will own the stock again. If there are customers for their liver tissues then they need to tell investors who have been investing in the company in hopes of returns. Unfortunately I have seen no evidence of significant demand for these tissues. I have seen misleading statements of how great their tissues are in an effort to keep retail investors interested in order fund their research program. Perhaps the reason that we don't hear about any sales or interest in these tissues is because companies really don't see the benefit of using these tissues for testing liver toxicity?
Overall I've been following this stock for about a year and I've been invested for much of that time. I spend a lot of my free time researching the company and the technology. And unfortunately I think it's time to sell. I wish it wasn't so but I don't use hope as an investment strategy.
I want to own the stock more than anything. I want to believe in the story. Unfortunately reality might be different. This company has not demonstrated any potential for significant returns until far in the future. As far as I can tell the only hope for significant returns is when they can create organs and this won't happen for many years.
When the company demonstrates that it is more than just a research organization I will own the stock again. If there are customers for their liver tissues then they need to tell investors who have been investing in the company in hopes of returns. Unfortunately I have seen no evidence of significant demand for these tissues. I have seen misleading statements of how great their tissues are in an effort to keep retail investors interested in order fund their research program. Perhaps the reason that we don't hear about any sales or interest in these tissues is because companies really don't see the benefit of using these tissues for testing liver toxicity?
Recent VIVS News
- VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing • GlobeNewswire Inc. • 04/28/2026 12:05:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/06/2026 05:27:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2026 08:05:10 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 04/02/2026 08:00:55 PM
- VivoSim Announces Pricing of up to a $4 Million Public Offering • GlobeNewswire Inc. • 04/01/2026 12:05:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 03/31/2026 02:17:06 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 03/27/2026 09:26:52 PM
- VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs • GlobeNewswire Inc. • 03/24/2026 12:05:00 PM
- VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales • GlobeNewswire Inc. • 03/03/2026 01:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/11/2026 09:05:26 PM
- VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego • GlobeNewswire Inc. • 02/11/2026 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2026 12:59:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2026 12:51:43 AM
- VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China • GlobeNewswire Inc. • 01/29/2026 09:05:00 PM
- VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer • GlobeNewswire Inc. • 01/06/2026 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2025 09:05:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/26/2025 11:07:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 09:01:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2025 09:08:13 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/03/2025 09:07:49 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/03/2025 09:06:32 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/28/2025 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/22/2025 12:45:18 AM
